Efficacy of Paracetamol for the Treatment of Patent Ductus Arteriosus in Preterm Neonates

Overview

Journal Ital J Pediatr

Publisher Biomed Central

Specialty Pediatrics

Date 2014 Feb 22

PMID 24555510

Citations 18

Authors

Gianluca Terrin

Francesca Conte

Antonella Scipione

Erica Bacchio

Maria Giulia Conti

Rosalia Ferro

Flavia Ventriglia

Mario De Curtis

Affiliations

Soon will be listed here.

Abstract

Inhibitors of the cyclo-oxygenase component of prostaglandin-H2 synthetase, namely indomethacin and ibuprofen, are commonly used in the treatment of hemodynamically significant patent ductus arteriosus. These drugs are associated with serious adverse events, including gastrointestinal perforation, renal failure and bleeding. The role of paracetamol, an inhibitor of the peroxidase component of prostaglandin-H2 synthetase, has been proposed for the treatment of patent ductus arteriosus. We report a series of 8 neonates (birth weight: 724 ± 173 g; gestational age: 26 ± 2 weeks) treated with paracetamol for a hemodynamically significant patent ductus arteriosus, because of contraindications to ibuprofen or indomethacin. Successful closure was achieved in 6 out of 8 babies (75%). Median ductal diameter was significantly reduced after treatment (from 1.2 mm, range 1.0-2.5 mm to 0.6 mm, range 0.0-2.5 mm, p = 0.038). No adverse or side effects were observed during treatment. On the basis of these results, paracetamol could be considered a promising and safe therapy for the treatment of patent ductus arteriosus in neonates.

Citing Articles

iPAPP: study protocol for a multicentre randomised controlled trial comparing safety and efficacy of intravenous paracetamol and indomethacin for the treatment of patent ductus arteriosus in preterm infants.

Namba F, Honda M, Sakatani S, Motojima Y, Kikuchi K, Sako M BMJ Open. 2023; 13(3):e069314.

PMID: 36958775 PMC: 10039996. DOI: 10.1136/bmjopen-2022-069314.

Comparison of Therapeutic Effect and Safety of Oral and Rectal Use of Acetaminophen on Patent Ductus Arteriosus in Preterm Infants: Clinical Randomized Trial.

Vakiliamini M, Daryoushi H, Babai H, Chegene Lorestani R, Rostamian M, Akya A Glob Pediatr Health. 2023; 10:2333794X231152116.

PMID: 36733954 PMC: 9887655. DOI: 10.1177/2333794X231152116.

Dual medication therapy (acetaminophen and ibuprofen) for the management of patent ductus arteriosus in preterm infants: a systematic review and meta-analysis.

Shah S, Makker K, Zhang M, Harnett S, Aziz K, Hudak M J Perinatol. 2022; 42(12):1654-1661.

PMID: 36008521 DOI: 10.1038/s41372-022-01500-8.

Different approaches for patent ductus arteriosus in premature infants using acetaminophen.

Surak A, Jain A, Hyderi A World J Pediatr. 2022; 18(4):243-250.

PMID: 35253098 DOI: 10.1007/s12519-022-00526-4.

Paracetamol (acetaminophen) use in infants and children was never shown to be safe for neurodevelopment: a systematic review with citation tracking.

Cendejas-Hernandez J, Sarafian J, Lawton V, Palkar A, Anderson L, Lariviere V Eur J Pediatr. 2022; 181(5):1835-1857.

PMID: 35175416 PMC: 9056471. DOI: 10.1007/s00431-022-04407-w.

References

Van der Westhuizen J, Kuo P, Reed P, Holder K . Randomised controlled trial comparing oral and intravenous paracetamol (acetaminophen) plasma levels when given as preoperative analgesia. Anaesth Intensive Care. 2011; 39(2):242-6. DOI: 10.1177/0310057X1103900214. View

Ozdemir O, Dogan M, Kucuktasci K, Ergin H, Sahin O . Paracetamol therapy for patent ductus arteriosus in premature infants: a chance before surgical ligation. Pediatr Cardiol. 2013; 35(2):276-9. DOI: 10.1007/s00246-013-0770-9. View

Shorter N, Liu J, Mooney D, Harmon B . Indomethacin-associated bowel perforations: a study of possible risk factors. J Pediatr Surg. 1999; 34(3):442-4. DOI: 10.1016/s0022-3468(99)90495-5. View

Strauss R . Anaemia of prematurity: pathophysiology and treatment. Blood Rev. 2010; 24(6):221-5. PMC: 2981681. DOI: 10.1016/j.blre.2010.08.001. View

Clyman R . Mechanisms regulating the ductus arteriosus. Biol Neonate. 2006; 89(4):330-5. DOI: 10.1159/000092870. View

Vandenberg K . Individualized developmental care for high risk newborns in the NICU: a practice guideline. Early Hum Dev. 2007; 83(7):433-42. DOI: 10.1016/j.earlhumdev.2007.03.008. View

Hammerman C, Bin-Nun A, Markovitch E, Schimmel M, Kaplan M, Fink D . Ductal closure with paracetamol: a surprising new approach to patent ductus arteriosus treatment. Pediatrics. 2011; 128(6):e1618-21. DOI: 10.1542/peds.2011-0359. View

Fujii A, Brown E, Mirochnick M, OBrien S, Kaufman G . Neonatal necrotizing enterocolitis with intestinal perforation in extremely premature infants receiving early indomethacin treatment for patent ductus arteriosus. J Perinatol. 2002; 22(7):535-40. DOI: 10.1038/sj.jp.7210795. View

McNamara P, Sehgal A . Towards rational management of the patent ductus arteriosus: the need for disease staging. Arch Dis Child Fetal Neonatal Ed. 2007; 92(6):F424-7. PMC: 2675381. DOI: 10.1136/adc.2007.118117. View

10.

Yurttutan S, Oncel M, Arayici S, Uras N, Altug N, Erdeve O . A different first-choice drug in the medical management of patent ductus arteriosus: oral paracetamol. J Matern Fetal Neonatal Med. 2012; 26(8):825-7. DOI: 10.3109/14767058.2012.755162. View

11.

Akima S, Kent A, Reynolds G, Gallagher M, Falk M . Indomethacin and renal impairment in neonates. Pediatr Nephrol. 2004; 19(5):490-3. DOI: 10.1007/s00467-003-1402-z. View

12.

Ohlsson A, Walia R, Shah S . Ibuprofen for the treatment of patent ductus arteriosus in preterm and/or low birth weight infants. Cochrane Database Syst Rev. 2013; (4):CD003481. DOI: 10.1002/14651858.CD003481.pub5. View

13.

Dang D, Wang D, Zhang C, Zhou W, Zhou Q, Wu H . Comparison of oral paracetamol versus ibuprofen in premature infants with patent ductus arteriosus: a randomized controlled trial. PLoS One. 2013; 8(11):e77888. PMC: 3817181. DOI: 10.1371/journal.pone.0077888. View

14.

Clyman R, Chemtob S . Vessel remodeling in the newborn: platelets fill the gap. Nat Med. 2010; 16(1):33-5. DOI: 10.1038/nm0110-33. View

15.

Oncel M, Yurttutan S, Erdeve O, Uras N, Altug N, Oguz S . Oral paracetamol versus oral ibuprofen in the management of patent ductus arteriosus in preterm infants: a randomized controlled trial. J Pediatr. 2013; 164(3):510-4.e1. DOI: 10.1016/j.jpeds.2013.11.008. View

16.

Dani C, Bertini G, Corsini I, Elia S, Vangi V, Pratesi S . The fate of ductus arteriosus in infants at 23-27 weeks of gestation: from spontaneous closure to ibuprofen resistance. Acta Paediatr. 2008; 97(9):1176-80. DOI: 10.1111/j.1651-2227.2008.00871.x. View

17.

Bagnoli F, Rossetti A, Messina G, Mori A, Casucci M, Tomasini B . Treatment of patent ductus arteriosus (PDA) using ibuprofen: renal side-effects in VLBW and ELBW newborns. J Matern Fetal Neonatal Med. 2012; 26(4):423-9. DOI: 10.3109/14767058.2012.733775. View

18.

Tekgunduz K, Ceviz N, Demirelli Y, Olgun H, Caner I, Sahin I . Intravenous paracetamol for patent ductus arteriosus in premature infants - a lower dose is also effective. Concerning the article by M.Y. Oncel et al: Intravenous paracetamol treatment in the management of patent ductus arteriosus in extremely low.... Neonatology. 2013; 104(1):6-7. DOI: 10.1159/000348568. View

19.

Oncel M, Yurttutan S, Uras N, Altug N, Ozdemir R, Ekmen S . An alternative drug (paracetamol) in the management of patent ductus arteriosus in ibuprofen-resistant or contraindicated preterm infants. Arch Dis Child Fetal Neonatal Ed. 2012; 98(1):F94. DOI: 10.1136/archdischild-2012-302044. View

20.

Hamrick S, Hansmann G . Patent ductus arteriosus of the preterm infant. Pediatrics. 2010; 125(5):1020-30. DOI: 10.1542/peds.2009-3506. View